

# Aurelian Amiot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/802141/publications.pdf>

Version: 2024-02-01

101  
papers

2,862  
citations

172386

29  
h-index

189801

50  
g-index

103  
all docs

103  
docs citations

103  
times ranked

3545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 579-588.	0.9	13
2	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1671-1686.e16.	2.4	15
3	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 787-797.e2.	2.4	11
4	Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. <i>Digestive and Liver Disease</i> , 2022, 54, 309-315.	0.4	10
5	P140 Immunomodulators are protective against severe COVID 19: results from a large multicentre cohort of inflammatory bowel disease patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i222-i223.	0.6	0
6	P558 Should we introduce early a new biological agent in patients with Inflammatory Bowel Disease after anti-TNF discontinuation due to severe anti-TNF-induced skin lesions? A multicenter cohort study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i502-i503.	0.6	0
7	DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i120-i120.	0.6	0
8	Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 79-91.	1.4	2
9	How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1202-1210.	0.6	1
10	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	1
11	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. <i>Scientific Reports</i> , 2022, 12, 7140.	1.6	45
12	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. <i>Digestive and Liver Disease</i> , 2022, 54, 1350-1357.	0.4	0
13	Rituximab or rituximab plus chlorambucil for translocation (11;18)-negative gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomized observational study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2597-2603.	0.6	1
14	Paradoxical reactions and biologic agents: a French cohort study of 9303 patients. <i>British Journal of Dermatology</i> , 2022, 187, 676-683.	1.4	6
15	Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. <i>Digestive and Liver Disease</i> , 2022, 54, 1162-1167.	0.4	6
16	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1454-1462.	0.6	8
17	Experience with the use of a hemostatic powder in 152 patients undergoing urgent endoscopy for gastrointestinal bleeding. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101558.	0.7	6
18	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1602-1610.e1.	2.4	26

#	ARTICLE	IF	CITATIONS
19	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. <i>Digestive and Liver Disease</i> , 2021, 53, 35-43.	0.4	16
20	Effectiveness and Safety of Subcutaneous Rituximab for Patients With Gastric MALT Lymphoma: A Caseâ€“Control Comparison With Intravenous Rituximab. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e32-e38.	0.2	4
21	Patientsâ€™ real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. <i>Digestive and Liver Disease</i> , 2021, 53, 434-441.	0.4	1
22	Editorial: determining disability in inflammatory bowel diseaseâ€”â€œSee(k) and you shall findâ€œ. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1323-1323.	1.9	1
23	Editorial: a long way to go before precision medicine. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 187-187.	1.9	0
24	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 944-951.	1.9	24
25	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 766-773.	0.6	11
26	Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 460-470.	1.9	49
27	ENDOSCOPIC TRAINING DURING FELLOWSHIP: A NATIONWIDE FRENCH STUDY. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101837.	0.7	0
28	Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 400-409.	1.9	6
29	Outcomes after double switching from originator Infliximab to biosimilar CTâ€“P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12â€“month prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 887-899.	1.9	19
30	Determinants of IBDâ€“related disability: a crossâ€“sectional survey from the GETAID. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1098-1107.	1.9	9
31	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 620-627.e1.	2.4	21
32	Efficacy of a tailored PCR-guided triple therapy in the treatment of <i>Helicobacter pylori</i> infection. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 492-499.	5.1	28
33	Colonic mucosa-associated lymphoid tissue lymphoma: a case series. <i>Leukemia and Lymphoma</i> , 2020, 61, 582-587.	0.6	9
34	Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020, 52, 268-273.	0.4	49
35	Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 628-636.	2.4	12
36	A clinical decision support tool may help to optimise vedolizumab therapy in Crohnâ€™s disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 553-564.	1.9	30

#	ARTICLE	IF	CITATIONS
37	The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab. <i>Digestive and Liver Disease</i> , 2020, 52, 1148-1155.	0.4	13
38	P248 Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S272-S272.	0.6	5
39	Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. <i>Digestive and Liver Disease</i> , 2020, 52, 1323-1330.	0.4	3
40	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. <i>American Journal of Gastroenterology</i> , 2020, 115, 1812-1820.	0.2	50
41	Predictors of mortality following emergency open colectomy for ischemic colitis: a single-center experience. <i>World Journal of Emergency Surgery</i> , 2020, 15, 40.	2.1	8
42	Choleperitoneum Fistula Associated with Ampullary Carcinoma: Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 833-835.	0.3	0
43	Letter: new insights on tofacitinib dose de-escalation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 578-578.	1.9	0
44	Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 609-618.	0.7	4
45	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
46	Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1096-1104.	1.9	19
47	Letter: immunogenicity of infliximab "ready for routine prediction?". <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 812-812.	1.9	1
48	The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 948-957.	1.9	84
49	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1039-1046.	1.9	54
50	Letter: severe COVID-19 infection and biologic therapies "a cohort study of 7 808 patients in France. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1245-1248.	1.9	5
51	Letter: long-term outcomes of patients with acute severe ulcerative colitis after intravenous steroid therapy "authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1252-1252.	1.9	0
52	P715 Real-world tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S478-S479.	0.6	3
53	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 40-53.	1.9	46
54	Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1001-1014.	1.4	18

#	ARTICLE	IF	CITATIONS
55	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1239-1247.	0.6	38
56	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1121-1130.	0.6	16
57	Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. <i>Digestive and Liver Disease</i> , 2019, 51, 1652-1660.	0.4	9
58	Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease: A multicenter, retrospective, observational study. <i>Digestive and Liver Disease</i> , 2019, 51, 236-241.	0.4	14
59	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 485-493.	1.9	91
60	Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 588-595.	1.9	73
61	Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. <i>Cut</i> , 2018, 67, 237-243.	6.1	119
62	Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn's Disease in Sustained Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 234-243.e2.	2.4	71
63	Endoscopic training: A nationwide survey of French fellows in gastroenterology. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 160-167.	0.7	1
64	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 59-67.	2.4	52
65	Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. <i>Digestive and Liver Disease</i> , 2018, 50, 181-188.	0.4	13
66	P593 Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S408-S408.	0.6	0
67	Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 831-838.	1.9	2
68	P528 Patients' perspectives on switching from reference infliximab to CT-P13 biosimilar in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S373-S374.	0.6	4
69	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	1.9	10
70	2017 WSES guidelines for the management of iatrogenic colonoscopy perforation. <i>World Journal of Emergency Surgery</i> , 2018, 13, 5.	2.1	53
71	Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. <i>Digestive and Liver Disease</i> , 2017, 49, 397-404.	0.4	27
72	Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2057-2064.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Laparoscopic vs. open surgery for the treatment of iatrogenic colonoscopic perforations: a systematic review and meta-analysis. <i>World Journal of Emergency Surgery</i> , 2017, 12, 8.	2.1	32
74	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 930-935.	0.6	34
75	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 310-321.	1.9	128
76	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	1.9	23
77	Patients' comorbidities reduce the clinical value of emergency colonoscopy: results of a retrospective cohort study. <i>Endoscopy International Open</i> , 2017, 05, E1119-E1127.	0.9	3
78	Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 473-480.	1.1	10
79	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168
80	Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1179-1185.	0.6	53
81	Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 165-165.	1.9	0
82	Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant <i>Helicobacter pylori</i> strains. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 517-524.	0.7	41
83	Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 90-98.	0.7	35
84	Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 242-250.e2.	2.4	155
85	The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1192-1199.	1.9	18
86	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 66-82.	1.4	115
87	Urgences digestives. <i>Anesthésie &amp; Réanimation</i> , 2015, 1, S17-S21.	0.1	0
88	Rituximab, alkylating agents or combination therapy for gastric mucosa-associated lymphoid tissue lymphoma: a monocentric non-randomised observational study. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 619-628.	1.9	19
89	Upper gastrointestinal obstruction due to trichobezoar. <i>Presse Medicale</i> , 2014, 43, 1008-1009.	0.8	2
90	Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. <i>Digestive and Liver Disease</i> , 2014, 46, 695-700.	0.4	31

#	ARTICLE	IF	CITATIONS
91	The Detection of the Methylated Wif-1 Gene Is More Accurate than a Fecal Occult Blood Test for Colorectal Cancer Screening. PLoS ONE, 2014, 9, e99233.	1.1	42
92	Tu1137 Hemophagocytic Syndrome During Inflammatory Bowel Disease (IBD): A Serious and Unfamiliar Complication of Immunosuppressive Therapy. Gastroenterology, 2013, 144, S-771-S-772.	0.6	1
93	Determinants of home parenteral nutrition dependence and survival of 268 patients with non-malignant short bowel syndrome. Clinical Nutrition, 2013, 32, 368-374.	2.3	186
94	Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leukemia and Lymphoma, 2013, 54, 940-944.	0.6	29
95	Long-term outcome after extensive intestinal resection for chronic radiation enteritis. Digestive and Liver Disease, 2013, 45, 110-114.	0.4	19
96	Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease?. Therapeutic Advances in Gastroenterology, 2013, 6, 215-229.	1.4	120
97	Prognostic yield of esophageal manometry in chronic intestinal pseudo-obstruction: a retrospective cohort of 116 adult patients. Neurogastroenterology and Motility, 2012, 24, 1008.	1.6	33
98	Long-Term Outcome of Chronic Intestinal Pseudo-Obstruction Adult Patients Requiring Home Parenteral Nutrition. American Journal of Gastroenterology, 2009, 104, 1262-1270.	0.2	102
99	Frequency of Mitochondrial Defects in Patients With Chronic Intestinal Pseudo-Obstruction. Gastroenterology, 2009, 137, 101-109.	0.6	64
100	Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion. JOP: Journal of the Pancreas, 2008, 9, 339-45.	1.5	15
101	The impact of COVID-19 on patients with IBD in a prospective European cohort study. Journal of Crohn's and Colitis, 0, , .	0.6	5